BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 12154045)

  • 21. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
    Eguchi J; Hiroishi K; Ishii S; Mitamura K
    Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.
    Rodolfo M; Zilocchi C; Cappetti B; Parmiani G; Melani C; Colombo MP
    Gene Ther; 1999 May; 6(5):865-72. PubMed ID: 10505112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S; Chuluyan E; Bravo A; Berenstein M; Klein S; Jasnis M; Carbone C; Chernajovsky Y; Podhajcer OL
    Cancer Res; 2000 Dec; 60(23):6696-703. PubMed ID: 11118055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
    Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
    Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells.
    Shan BE; Hao JS; Li QX; Tagawa M
    Cell Mol Immunol; 2006 Feb; 3(1):47-52. PubMed ID: 16549049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
    Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.
    Thibodeaux DK; Hunter SE; Waldburger KE; Bliss JL; Trepicchio WL; Sypek JP; Dunussi-Joannopoulos K; Goldman SJ; Leonard JP
    J Immunol; 1999 Nov; 163(10):5257-64. PubMed ID: 10553047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
    Hafner M; Falk W; Echtenacher B; Männel DN
    Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.
    Nakajima C; Uekusa Y; Iwasaki M; Yamaguchi N; Mukai T; Gao P; Tomura M; Ono S; Tsujimura T; Fujiwara H; Hamaoka T
    Cancer Res; 2001 Apr; 61(8):3399-405. PubMed ID: 11309299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I; Chu TM
    Mol Biother; 1992 Mar; 4(1):47-52. PubMed ID: 1627274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.
    Maheshwari A; Han S; Mahato RI; Kim SW
    Gene Ther; 2002 Aug; 9(16):1075-84. PubMed ID: 12140735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 12-activated lymphocytes influence tumor genetic programs.
    Cavallo F; Quaglino E; Cifaldi L; Di Carlo E; André A; Bernabei P; Musiani P; Forni G; Calogero RA
    Cancer Res; 2001 Apr; 61(8):3518-23. PubMed ID: 11309316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
    Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
    Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response.
    Sturlan S; Schneeberger A; Fang M; Beinhauer BG; Lührs P; Kutil R; Wessner B; Huang L; Aasen AO; Rogy MA
    Anticancer Res; 2003; 23(6C):4843-51. PubMed ID: 14981934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
    Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
    Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
    Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
    J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
    Yang X; Chu Y; Wang Y; Zhang R; Xiong S
    J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.